| 林冬颜,辛红梅,林 静,梁华丽,羊柳美.消癌平注射液联合表柔比星新辅助化疗对三阴性乳腺癌患者免疫功能、生活质量及血清肿瘤标志物的影响[J].现代生物医学进展英文版,2021,(13):2543-2546. |
| 消癌平注射液联合表柔比星新辅助化疗对三阴性乳腺癌患者免疫功能、生活质量及血清肿瘤标志物的影响 |
| Effect of Xiaoaiping Injection Combined with Epirubicin Neoadjuvant Chemotherapy on Immune Function, Quality of Life and Serum Tumor Markers in Triple Negative Breast Cancer Patients |
| Received:November 24, 2020 Revised:December 18, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.13.030 |
| 中文关键词: 消癌平注射液 表柔比星 化疗 三阴性乳腺癌 免疫功能 生活质量 肿瘤标志物 |
| 英文关键词: Xiaoaiping injection Epirubicin Neoadjuvant chemotherapy Triple negative breast cancer Immune function Quality of life Tumor markers |
| 基金项目:海南省卫生厅医学科研基金项目(14A210246) |
|
| Hits: 830 |
| Download times: 525 |
| 中文摘要: |
| 摘要 目的：探讨消癌平注射液联合表柔比星新辅助化疗对三阴性乳腺癌（TNBC）患者免疫功能、生活质量及血清肿瘤标志物的影响。方法：选取TNBC患者89例，按照随机数字表法分为对照组和研究组，对照组（n=44）患者给予表柔比星新辅助化疗治疗，研究组（n=45）患者给予消癌平注射液联合表柔比星新辅助化疗。对比两组疗效、免疫功能、生活质量、血清肿瘤标志物及不良反应。结果：研究组治疗12周后的临床总有效率为91.11%（41/45），高于对照组的63.64%（28/44）（P<0.05）。两组治疗12周后健康调查简表（SF-36）量表各维度评分升高，且研究组较对照组高（P<0.05）。两组治疗12周后CD4+CD25+Treg、Th17/ Treg均降低，且研究组较对照组低（P<0.05），Th17升高，且研究组较对照组高（P<0.05）。两组治疗12周后癌胚抗原（CEA）、糖类抗原199（CA199）、糖类抗原125（CA125）均降低，且研究组较对照组低（P<0.05）。两组不良反应发生率对比未见差异（P>0.05）。结论：消癌平注射液联合表柔比星新辅助化疗治疗TNBC，具有确切的治疗效果，可降低血清肿瘤标志物水平，改善患者免疫功能和生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of xiaoaiping injection combined with epirubicin neoadjuvant chemotherapy on immune function, quality of life and serum tumor markers in patients with triple negative breast cancer(TNBC). Methods: 89 patients with TNBC were selected, and divided into control group and study group by random number table method. The control group (n=44) was given epirubicin neoadjuvant chemotherapy, while the study group (n=45) was given xiaoaiping injection combined with epirubicin neoadjuvant chemotherapy. The efficacy, immune function, quality of life, serum tumor markers and adverse reactions were compared between two groups. Results: The clinical total effective rate of the study group at 12 weeks after treatment was 91.11%(41/45), which was higher than 63.64%(28/44) of the control group (P<0.05). 12 weeks after treatment, 36-item short form (SF-36) scores of all dimension of the two groups increased, and the study group was higher than the control group(P<0.05). 12 weeks after treatment, CD4+CD25+ Treg and Th17 / Treg in the two groups were decreased, and the study group was lower than the control group(P<0.05), and Th17 was increased, and the study group was higher than the control group (P<0.05). 12 weeks after treatment, the levels of carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and carbohydrate antigen 125 (CA125) in the two groups were decreased, and the study group was lower than the control group(P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Xiaoaiping injection combined with epirubicin neoadjuvant chemotherapy in the treatment of TNBC has definite therapeutic effect, reduces serum tumor marker level, improves immune function and quality of life of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
